Page 235 - Haematologica Vol. 109 - July 2024

ARTICLE - ICARIA-MM final overall survival analysis
P.G. Richardson et al.
lenalidomide (OPTIMISMM): a randomised, open-label, phase 3
trial. Lancet Oncol. 2019;20(6):781-794.
24. Beksac M, Richardson P, Oriol A, et al. Pomalidomide,
bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial. Clin Lymphoma Myeloma Leuk. 2023;23:S27-S28.
25. Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016;27(3):373-378.
26. Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.
Haematologica | 109 July 2024
2249